AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

Amgen (NASDAQ: AMGN) will present at the Goldman Sachs 46 th Annual Global Healthcare Conference at 9:20 a.m. PT on Tuesday, June 10, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Jay Bradner, executive vice president of Research and Development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.

In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , YouTube and Threads .

CONTACT: Amgen, Thousand Oaks
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (investors)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-goldman-sachs-46th-annual-global-healthcare-conference-302473438.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

AMGN:US
The Conversation (0)
Invion Secures Expanded Photosoft Global Exclusive License

Invion Secures Expanded Photosoft Global Exclusive License

Invion Limited (IVX:AU) has announced Invion Secures Expanded Photosoft Global Exclusive LicenseDownload the PDF here. Keep Reading...
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions

Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven... Keep Reading...
Pink liquid being pipetted into rows of clear test tubes.

Transforming Disease Detection with AI-Driven Biological Insights

Artificial intelligence (AI) is fundamentally reshaping biotechnology and healthcare, unlocking the secrets hidden within complex biological data. Machine learning in genomics and proteomics is transforming how diseases are detected, monitored and treated. Central to this revolution are... Keep Reading...
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040

Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's... Keep Reading...
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases

The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume... Keep Reading...
Appendix 4C and Quarterly Activities Report - September 2025

Appendix 4C and Quarterly Activities Report - September 2025

Invion Limited (IVX:AU) has announced Appendix 4C and Quarterly Activities Report - September 2025Download the PDF here. Keep Reading...

Latest Press Releases

Related News